<?xml version="1.0" encoding="UTF-8"?>
<p>The first use of an EBOV kinetic model 
 <italic>in vivo</italic> was to characterize the curative efficacy of favipiravir in a mice model.
 <xref rid="psp412510-bib-0033" ref-type="ref">
  <sup>33</sup>
 </xref> Twenty IFNαR−/− mice infected with Makona strain EBOV received favipiravir 300 mg/day initiated at D6 (
 <italic>N</italic> = 5) or D8 (
 <italic>N</italic> = 5), or were left untreated (
 <italic>N</italic> = 10), leading to survival rates at D25 of 100%, 0%, and 0%, respectively.
</p>
